Patients and study procedures
non-ambulant
Eligible patients were non-ambulant and aged 2–25 years, with a genetically confirmed diagnosis of 5q-autosomal recessive SMA and clinical symptoms attributable to type 2 or type 3 SMA. Patients were excluded from the study if they had received treatment with an 